Clearwater, FL, December 13, 2012 -- Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE: A), Life Technologies Corporation (NASDAQ: LIFE) and Thermo Fisher Scientific, Inc. (NYSE: TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.
While it is rare for the always-reliable and steady life sciences industry to make waves in the press, one company with a long-lasting reputation of nearly a decade has recently forged something of a comeback, receiving headlines the likes of which many younger companies would be envious. Pressure BioSciences, Inc, (PBIO) currently trading at .22 cents with an average volume of 19,254, has been reporting record numbers throughout the year. PBIO is a life sciences company which focuses on the development and sale of pressure-based technologies used for analyzing cells and molecules in the fields of forensics, bio-marker discovery, vaccine development, and even counter-bioterror applications.
As demand for these technologies has ballooned over the past several years, Pressure BioSciences has reaped the benefits. In 2012, total sales for Quarter Three reached a 40% increase over the prior year period, and sales of their proprietary PCT (“Pressure Cycling Technology”) products and services climbed to a 37% increase. Grant revenue also increased significantly over that same period, while operating losses decreased.
If that isn’t a financially sound business model, we don’t know what is. And when it comes to financial investments, as anyone skeptical of Pressure BioSciences’ current surge of growth can not only look at the numbers, but also a handful of the Company’s recent accomplishments, to decide whether PBIO is a solid investment.
On November 26th, Pressure BioSciences greatly expanded its product line by entering into a two-way marketing, selling, and distribution agreement with Constant Systems, to offer that company’s “cell disruption equipment and consumables” to consumers all over North America. On the flip side, Constant Systems will offer PBIO’s PCT technologies in countries throughout Europe ? a move that exponentially increases Pressure BioSciences’ exposure and potential revenue, beginning immediately in Q1 2013.
Keen to express his enthusiasm for the deal, Pressure BioSciences, Inc. President and CEO Richard T. Schumacher was quoted as saying: “the two product lines complement each other exceedingly well. While both the CS and PBI technologies are based on high pressure, each product line has fundamental scientific capabilities that the other does not have. PBI’s PCT Platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects. CS’s technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing.”
This is great news not only for both of these companies, but also for PBIO’s diverse multitude of research-based consumers, which includes Harvard University, the FBI, and agricultural giant Monsanto, as the ability to access these complementary technologies from Pressure BioSciences, without having to negotiate with a third party or import technologies from overseas, will no doubt help make consumer operations run more economically and efficiently.
Pressure BioSciences is undoubtedly a seasoned company with a new agenda. In addition to their other recent accomplishments, including their distribution deal with Thermos Fisher’s subsidiary Cole Parmer (announced last month), their deal with Constant Systems alone guarantees them a wealth of new opportunities over the course of the next year, beginning immediately. Investors looking for an undervalued stock with the potential for serious short-term gains and long-term stability need look no further than PBIO.
Always read our full disclaimer/disclosure pertaining to this article
922 Mc Mullen Booth Rd
Clearwater FL 33759
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
SOURCE Seraphim Strategies